title: Carteolol incorporated into FAT-MLV liposomes: prolonged and decreased reduction of IOP.
abstract: Liposomes are used as carries providing a prolonged and improved drug action. They are capable of trapping beta-blockers such as Carteolol. In a randomized prospective double-blind clinical trial, Carteolol 2% suspended with frozen and thawed multivesicular large vesicles (FAT-MLV), FAT-MLV, and Carteolol 2% were applied to normal (slightly cataracterous) eyes and immediately after extracapsular cataract extraction or phakoemulsification with implantation of a posterior chamber lens in a standard procedure. Twenty-five patients were included in each group. Intraocular pressure (IOP) was measured for 3 days using applanation tonometry. In the normal eyes, a significant reduction of IOP was found for the patients receiving Carteolol and Carteolol MLV suspension. Moreover, an improved action and a prolongation of drug action was registered in the Carteolol/MLV group as compared to Carteolol treatment alone. After cataract operation, the control groups showed a significant increase in IOP. Carteolol produced a constant level of IOP but the Carteolol/MLV suspension showed a stronger decrease after ECCE and a still stronger decrease after phakoemulsification. Hence, Carteolol is suitable for the reduction of IOP but a Carteolol/MLV suspension is more effective, providing the possibility of a single application of a low-dose beta-blocker after cataract extraction with posterior chamber lens implantation.
authors: Augenklinik des Akademischen Lehrkrankenhauses Braunschweig.
authors: U
authors: U
authors: Weber
authors: C
authors: C
authors: Bähr
authors: L
authors: L
authors: Michaelis
authors: H
authors: H
authors: Mayer
authors: K
authors: K
authors: Wirth
mesh_terms: D002354:Carteolol / Q000008:administration & dosage*; D002387:Cataract Extraction / Q000009:adverse effects; D004311:Double-Blind Method; D004337:Drug Carriers; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007910:Lenses, Intraocular / Q000009:adverse effects; D008081:Liposomes; D009798:Ocular Hypertension / Q000188:drug therapy / Q000209:etiology; D010743:Phospholipids; D011446:Prospective Studies
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D010743:Phospholipids; D002354:Carteolol